NDAORALTABLET
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Mechanism of Action
Cytochrome P450 3A Inhibitors
Pharmacologic Class:
Cytochrome P450 3A Inhibitor
Clinical Trials (3)
Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain
Started Mar 2023
30 enrolled
HIV InfectionsObesity
Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)
Started Sep 2021
75 enrolled
HIV-1-infection
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
Started Sep 2019
1 enrolled
Human Immunodeficiency Virus
Loss of Exclusivity
LOE Date
Jul 19, 2038
150 months away
Patent Expiry
Jul 19, 2038